de Campos Daniel Rossi, Vieira Nelson Rogério, Bernasconi Gilberto, Barros Fabio Alessandro Proença, Meurer Eduardo César, Marchioretto Marco Antônio, Coelho Edvaldo Capobiango, Calafatti Silvana Aparecida, Sommer Carolina, Couto Jussara Moreira, Buranello Simoni, Silva Andréia Rodrigues Cristino, Amarante Antônio Ricardo, Abib Eduardo, Júnior José Pedrazzoli
Clinical Pharmacology and Gastroenterology Unit, São Francisco University Medical School, Bragança Paulista, SP (Brazil).
Arzneimittelforschung. 2007;57(6):309-14. doi: 10.1055/s-0031-1296624.
To compare the bioavailability of two pantoprazole (CAS 102625-70-7) formulations (40 mg pantoprazole enteric coated tablets) under fasted and fed conditions as well as to evaluate the dissolution profile in biorelevant media.
The subjects received either 40 mg of the reference or of test formulation in fasting (n = 28) and fed (n=70) condition. The studies were conducted according to a single dose and randomized crossover design. Blood samples were collected up to 12 h after drug administration in fasting condition and up to 48 h in fed condition. Plasma concentrations of pantoprazole were determined by LC-MS/MS. Pharmacokinetic parameters were calculated from the observed plasma concentration-time profiles. Bioequivalence between the formulations in fasting and fed condition was assessed considering 90% confidence intervals for the ratio of means for lnCmax and lnAUC(0-t) within 0.8-1.25. Dissolution profiles were evaluated in biorelevant media [Fasting State Simulating Intestinal Fluid (FaSSIF) and Fed State Simulating Intestinal Fluid (FeSSIF)]. The sameness of the dissolution curves was assessed by f2 values between 50 and 100.
Under fasting condition the 90% confidence interval for the ratio of means for the lnCmax, (0.94-1.03) and lnAUC(0-t) (0.89-0.99) was within the guideline range of bioequivalence (0.80-1.25). However, the data for lnCmax (0.51-0.76) and lnAUC(0-t) (0.68-0.90) under fed condition were not within the bioequivalence range. The postprandial study demonstrated a high intra-subject variability and in some subjects pantoprazole could not be detected for up to 24 h, although the dissolution profile of reference and test formulations presented a similar disposition in FaSSIF and FeSSIF as confirmed by the values of f2 higher than 50.
The results demonstrated that the test formulation was bioequivalent to the reference in fasting condition but not in postprandial state. The dissolution profile in FaSSIF indicates that this biorelevant medium was more adequate to discriminate the in vivo disposition of pantoprazole than FeSSIF. Furthermore, the fed condition study had shown a pronounced influence of food in the absorption of pantoprazole after single oral dose administration.
比较两种泮托拉唑(CAS 102625 - 70 - 7)制剂(40 mg泮托拉唑肠溶片)在禁食和进食条件下的生物利用度,并评估其在生物相关介质中的溶出曲线。
受试者在禁食(n = 28)和进食(n = 70)条件下分别接受40 mg的参比制剂或受试制剂。研究采用单剂量随机交叉设计。在禁食条件下给药后12 h内以及进食条件下给药后48 h内采集血样。采用LC - MS/MS测定血浆中泮托拉唑的浓度。根据观察到的血浆浓度 - 时间曲线计算药代动力学参数。考虑lnCmax和lnAUC(0 - t)均值比的90%置信区间在0.8 - 1.25内,评估禁食和进食条件下制剂之间的生物等效性。在生物相关介质[禁食状态模拟肠液(FaSSIF)和进食状态模拟肠液(FeSSIF)]中评估溶出曲线。通过50至100之间的f2值评估溶出曲线的一致性。
在禁食条件下,lnCmax均值比的90%置信区间(0.94 - 1.03)和lnAUC(0 - t)均值比的90%置信区间(0.89 - 0.99)在生物等效性指导范围内(0.80 - 1.25)。然而,进食条件下lnCmax(0.51 - 0.76)和lnAUC(0 - t)(0.68 - 0.90)的数据不在生物等效性范围内。餐后研究显示个体内变异性较高,在一些受试者中,长达24 h检测不到泮托拉唑,尽管参比制剂和受试制剂的溶出曲线在FaSSIF和FeSSIF中呈现相似的趋势,f2值高于50证实了这一点。
结果表明受试制剂在禁食条件下与参比制剂生物等效,但在餐后状态下并非如此。FaSSIF中的溶出曲线表明,这种生物相关介质比FeSSIF更适合区分泮托拉唑的体内处置情况。此外,进食条件下的研究表明,单次口服给药后,食物对泮托拉唑的吸收有显著影响。